Table 2. Medication possession ratio calculation.

Medication possession ratio	Intervention	Control	Mean difference (95% CI)	P Value
	n=94	n=98
Follow-up time, month	11.8 ± 1.1	12.1 ± 0.76	-0.34 (-0.6- -0.08)	<0.01 *
Total MPR for all medication
3 months MPRt	0.93 ± 0.09	0.92 ± 0.09	0.01 (-0.01–0.04)	0.18
6 months MPRt	0.94 ± 0.1	0.93 ± 0.09	0.01 (-0.01–0.04)	0.15
9 months MPRt	0.95 ± 0.1	0.93 ± 0.09	0.03 (-0.01–0.05)	0.04 *
12 months MPRt	0.95 ± 0.09	0.92 ± 0.09	0.03 (0.01–0.06)	0.02 *
Medication non-persistence	0.15 ± 0.21	0.22 ± 0.23	-0.07 (-0.13– -0.01)	0.02 *
Nonadherent (MPRt <0.8)	8 (8.5)	15 (15.9)	-	0.15
Antihyperglycaemic medication £
Regimen-specific MPRs	0.95 ± 0.09	0.92 ± 0.09	0.03 (0.01–0.06)	0.02 *
Regimen non-persistence	0.13 ± 0.16	0.22 ± 0.23	-0.09 (-0.19–0.01)	0.04 *
Nonadherent (MPRs <0.8) **	8 (8.5)	15 (15.9)	-	0.15
Antihypertensive medication £ ¥
Regimen-specific MPRs	0.95 ± 0.1	0.92 ± 0.08	0.04 (0.01–0.06)	<0.01 *
Regimen non-persistence	0.12 ± 0.09	0.15 ± 0.18	-0.03 (-0.09–0.04)	0.23
Nonadherent (MPRs <0.8) **	8 (9.3)	13 (13.8)	-	0.34
Antihyperlipidaemic medication £ #
Regimen-specific MPRs	0.96 ± 0.09	0.93 ± 0.08	0.04 (0.01–0.06)	<0.01 *
Regimen non-persistence	0.09 ± 0.1	0.13 ± 0.16	-0.04 (-0.11–0.02)	0.09
Nonadherent (MPRs <0.8) **	7 (7.7)	12 (12.5)	-	0.28

Data are M ± SD or n (%);

^*Significant P value <0.05;

^**Chi-squared test;

^£ At study exit;

^¥ MPIP (n=86), control (n=94);

^# MPIP (n=91), control (n=96); CL: confidence interval; MPRt: Total medication possession ratio; MPRs: Regimen-specific medication possession ratio, see data 1 in Underlying data. ⁴⁴